These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 16108016

  • 1. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.
    Mimeault M, Moore E, Moniaux N, Hénichart JP, Depreux P, Lin MF, Batra SK.
    Int J Cancer; 2006 Feb 15; 118(4):1022-31. PubMed ID: 16108016
    [Abstract] [Full Text] [Related]

  • 2. Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
    Mimeault M, Mehta PP, Hauke R, Henichart JP, Depreux P, Lin MF, Batra SK.
    Growth Factors; 2007 Dec 15; 25(6):400-16. PubMed ID: 18365871
    [Abstract] [Full Text] [Related]

  • 3. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
    Mimeault M, Johansson SL, Vankatraman G, Moore E, Henichart JP, Depreux P, Lin MF, Batra SK.
    Mol Cancer Ther; 2007 Mar 15; 6(3):967-78. PubMed ID: 17363490
    [Abstract] [Full Text] [Related]

  • 4. Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
    Mimeault M, Venkatraman G, Johansson SL, Moore E, Henichart JP, Depreux P, Lin MF, Batra SK.
    Int J Cancer; 2007 Jan 01; 120(1):160-9. PubMed ID: 17013895
    [Abstract] [Full Text] [Related]

  • 5. Synergistic antiproliferative and apoptotic effects induced by epidermal growth factor receptor and protein kinase a inhibitors in human prostatic cancer cell lines.
    Mimeault M, Pommery N, Hénichart JP.
    Int J Cancer; 2003 Aug 10; 106(1):116-24. PubMed ID: 12794766
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines.
    Mimeault M, Jouy N, Depreux P, Hénichart JP.
    Prostate; 2005 Feb 01; 62(2):187-99. PubMed ID: 15389789
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Epidermal growth factor receptor and hedgehog signaling pathways are active in esophageal cancer cells from rat reflux model.
    Sui G, Bonde P, Dhara S, Broor A, Wang J, Marti G, Feldmann G, Duncan M, Montgomery E, Maitra A, Harmon JW.
    J Surg Res; 2006 Jul 01; 134(1):1-9. PubMed ID: 16488438
    [Abstract] [Full Text] [Related]

  • 10. Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.
    Mimeault M, Johansson SL, Henichart JP, Depreux P, Batra SK.
    Mol Cancer Ther; 2010 Mar 01; 9(3):617-30. PubMed ID: 20179163
    [Abstract] [Full Text] [Related]

  • 11. Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.
    Bonaccorsi L, Marchiani S, Muratori M, Forti G, Baldi E.
    J Cancer Res Clin Oncol; 2004 Oct 01; 130(10):604-14. PubMed ID: 15258753
    [Abstract] [Full Text] [Related]

  • 12. Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
    Festuccia C, Gravina GL, Millimaggi D, Muzi P, Speca S, Ricevuto E, Vicentini C, Bologna M.
    Oncol Rep; 2007 Aug 01; 18(2):503-11. PubMed ID: 17611677
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
    Wu M, Yuan Y, Pan YY, Zhang Y.
    Mol Med Rep; 2014 Aug 01; 10(2):931-8. PubMed ID: 24840891
    [Abstract] [Full Text] [Related]

  • 15. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
    Qin B, Ariyama H, Baba E, Tanaka R, Kusaba H, Harada M, Nakano S.
    Cancer Chemother Pharmacol; 2006 Nov 01; 58(5):577-84. PubMed ID: 16532343
    [Abstract] [Full Text] [Related]

  • 16. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
    Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A.
    Clin Cancer Res; 2006 Jan 15; 12(2):617-25. PubMed ID: 16428508
    [Abstract] [Full Text] [Related]

  • 17. Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
    Sgambato A, Camerini A, Faraglia B, Ardito R, Bianchino G, Spada D, Boninsegna A, Valentini V, Cittadini A.
    J Cell Physiol; 2004 Oct 15; 201(1):97-105. PubMed ID: 15281092
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.
    Vicentini C, Festuccia C, Gravina GL, Angelucci A, Marronaro A, Bologna M.
    J Cancer Res Clin Oncol; 2003 Mar 15; 129(3):165-74. PubMed ID: 12712332
    [Abstract] [Full Text] [Related]

  • 20. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
    Song JY, Lee SW, Hong JP, Chang SE, Choe H, Choi J.
    Cancer Lett; 2009 Oct 08; 283(2):135-42. PubMed ID: 19380191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.